pramipexole

(redirected from Sifrol)
Also found in: Dictionary.
Related to Sifrol: pramipexole, Madopar

pramipexole

 [pram″ĭ-pek´sōl]
a dopamine agonist used in the form of the dihydrochloride salt in treatment of parkinson's disease, administered orally.

pramipexole

/pram·i·pex·ole/ (pram″ĭ-pek´sōl) a dopamine agonist used in the form of the dihydrochloride salt as an antidyskinetic in the treatment of Parkinson's disease.

pramipexole

(prăm′ə-pĕk′sōl′)
n.
A dopamine agonist used in the treatment of Parkinson's disease.

pramipexole

an antiparkinson agent.
indication It is used to treat parkinsonism.
contraindication Known hypersensitivity prohibits its use.
adverse effects Life-threatening effects are hemolytic anemia, leukopenia, and agranulocytosis. Other adverse effects include psychosis, hallucination, depression, dizziness, constipation, impotence, and blurred vision. Common side effects include agitation, insomnia, nausea, anorexia, and orthostatic hypotension.

pramipexole

Mirapex® Neurology A dopamine antagonist used to manage Parkinson's disease Adverse effects Constipation, dry mouth, vision defects, insomnia
References in periodicals archive ?
La Comision de Transparencia de la Alta Autoridad en Salud de Francia (Haute Autorite en Sante, HAS) considera que el servicio medico proporcionado por el medicamento Sifrol [R] es importante solamente en las formas muy severas del sindrome de piernas inquietas idiopatico.
Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company's outlook
Successful lifecycle management is expected to help Flomax and Sifrol continue to contribute strong sales in spite of patent loss and increased competition, thus avoiding the same fate as Mobic.